<DOC>
	<DOC>NCT02949960</DOC>
	<brief_summary>The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild to moderate atopic dermatitis (AD).</brief_summary>
	<brief_title>DMT210 Topical Gel in the Treatment of Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male or female 12 years or older Patient has chronic, stable AD that has been present for at least 3 months with 535% (inclusive) BSA (Body Surface Area) of AD involvement Patient has two analogous, Target Lesions; one lesion within each of the two Treatment Areas Patient is willing and able to comply with the protocol Patient has used topical therapies for AD within the Treatment Areas 2 weeks before baseline</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Eczema</keyword>
	<keyword>Dermatitis</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Skin Diseases, Genetic</keyword>
	<keyword>Dermatitis, Atopic</keyword>
	<keyword>Skin Diseases, Eczematous</keyword>
	<keyword>Hypersensitivity</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>